Drug Therapies for Kidney Cancer

There are many targeted therapies and multiple immunotherapies. Your doctor will review your tests, staging and history and discuss the treatment options that make are appropriate for you.

Will I need drug therapy for my kidney cancer? Which drug therapy is right for me?

A list of approved drugs and links to more information, including financial support information are given below

ADJUVANT THERAPY

Often given when the patient may be at high risk for a disease recurrence, even after the tumor and/or affected kidney have been surgically removed.

Options for Advanced Kidney Cancer

When kidney cancer has spread to other organs, the cancer is usually not completely curable. The goal of treatment is therefore to make life as long and as normal as possible. Combinations of different treatments may be recommended.

Options for line treatments for advanced kidney cancer

What are my choices and how do we select a therapy? Most patients start with a combination of two immunotherapies (IO/IO) or a TKI (a targeted cancer therapy) combined with an immunotherapy. Learn more about your choices for your first line of treatment with the useful discussions from CURE TODAY.

Immunotherapy and Immune Checkpoint Inibitors (ICI’s)

Learn more about TKI/Immunotherapy combinations as a first line treatment or in later lines by clicking the link below.

Duel Immunotherapy

Learn more about IO/IO combinations (also called Dual immunotherapy or Dual checkpoint inhibition) as a first line treatment or in later lines.

I had more than one choice as a suggested treatment. How do I get ready to give my input?

IKCC and KidneyCAN patients and their families have an essential role to play in healthcare decisions that affect their lives. The IKCC shared decision aid series is written for people with kidney cancer, their caregivers and families. The booklets are written by a team of patients, patient advocates and medical professionals.

Immunotherapy and Immune Checkpoint Inhibitors (ICI’s)

An important part of the immune system is its ability to keep itself from attacking normal cells in the body. To do this, it uses “checkpoints,” which are proteins on immune cells that need to be turned on (or off) to start an immune response. Kidney cancer cells sometimes use these checkpoints to avoid being attacked by the immune system. But these drugs target the checkpoint proteins, helping to restore the immune response against the cancer cells.

Targeted Therapy Drugs

Targeted therapy is a type of cancer treatment that uses drugs or other substances to precisely identify and attack certain types of cancer cells. A targeted therapy can be used by itself or in combination with other treatments.

IO/IO also known as Dual checkpoint inhibition

For selected patients ipilimumab can be given with nivolumab (a PD-1 inhibitor) for 4 doses followed by nivolumab alone.

We currently only have one FDA approved combination of immunotherapy drugs but others are being tested in clinical trials.

TKI / IO
Axitinib (Inlyta) + Pembrolizumab (Keytruda)

TKI / IO
Cabozantinib (Cabometyx)+Nivolumab (Opdivo)

TKI / IO
Lenvatinib (Lenvima) +Pembrolizumab (Keytruda)

TKI / IO
Axitinib (Inlyta) + Pembrolizumab (Keytruda)

One of my choices was a clinical trial. I want to learn more before I decide.

Clinical trials are research studies that involve people. Any time you or a loved one need treatment for cancer, clinical trials are an option to think about. Learning all you can about clinical trials can help you talk with your doctor and decide what is right for you.

Understanding Your Kidney Cancer Diagnosis

GO TO PAGE

Visit

Building a Care Team

GO TO PAGE

Visit

Treatment & Trial Options

GO TO PAGE

Visit

Living Well with Kidney Cancer

GO TO PAGE

Visit

WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORS →

DONATE →

CONTACT →

Latest News

Michael Whitley: A Kidney Cancer Diagnosis “Cracked Me Open”

Michael Whitley: A Kidney Cancer Diagnosis “Cracked Me Open”

Michael Whitley is 45 years old and lives in Huntsville, Alabama, with his boyfriend, Michael Mueller. He's the owner and Chief Operating Officer of EngeniusMicro, a techonology-development company focused on defense contracting. Following his kidney cancer diagnosis in 2019, Michael wanted to...

DISTRICT DAYS 2022 →

SPRING ADVOCACY DAYS 2022 →

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DONATE NOW →

CONTACT →

Latest News

District Days: Asking Congress to Fund Kidney Cancer Research

District Days: Asking Congress to Fund Kidney Cancer Research

On August 8-9th, KidneyCAN gathered advocates from all over the United States to ask Congress for robust funding for kidney cancer research through the NIH and CDMRP (Congressionally Directed Medical Research Programs). Read on to hear about our goals for this event and how you can help fund...

Patient Resource Center

UNDERSTANDING YOUR KIDNEY CANCER DIAGNOSIS

BUILDING YOUR CARE TEAM

TREATMENT & TRIAL OPTIONS

LIVING WELL WITH KIDNEY CANCER

CLINICAL TRIALS →

IMMUNOTHERAPY →

KCRS: KIDNEY CANCER RESEARCH SUMMIT →

RESEARCH OPPORTUNITIES →

NEWS →

Latest News

District Days: Asking Congress to Fund Kidney Cancer Research

District Days: Asking Congress to Fund Kidney Cancer Research

On August 8-9th, KidneyCAN gathered advocates from all over the United States to ask Congress for robust funding for kidney cancer research through the NIH and CDMRP (Congressionally Directed Medical Research Programs). Read on to hear about our goals for this event and how you can help fund...

SUPPORT OUR WORK →

ROCK THE RUN →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

In Memory of Gary Poteat: A Hard Worker, a Helper, a Teacher

In Memory of Gary Poteat: A Hard Worker, a Helper, a Teacher

Gary Poteat was the husband of Susan Poteat, KidneyCAN's Medical Science Liaison. Gary and Susan were married for 43 years. Since Gary's diagnosis of Stage IV kidney cancer in 2007, both Gary and Susan have been active advocates for research funding and trial participation. The KidneyCAN community...